La agencia británica de medicamentos (Medicines and Healthcare Products Regulatory Agency, MHRA) ha reclasificado las soluciones orales de codeína (codeine linctus) de medicamento de venta exclusiva en farmacias (pharmacy-only medicine) a medicamento sujeto a prescripción médica (prescription-only medicine, POM). Esta decisión responde a un uso indebido creciente, ya que se ha desviado su uso t...
This article is for subscribers only
Login to your account to continue reading.
This publication is restricted to registered pharmacists, and its dissemination among the general public or other health professionals is not intended.
Listen to this article
